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Introduction 
 
Fibrosis is characterized by an excessive deposition of extracellular matrix components, 
predominantly of collagens. Fibrotic changes have been observed in various diseases affecting 
different organs such as the skin, lung, liver and kidney. Current concepts of fibrogenesis 
suggest a cascade of events similar to wound-healing (1, 2). An initial trigger or injury 
activates resident cells, which produce pro-inflammatory mediators. The resulting gradient of 
chemotactic cytokines guides the infiltration of inflammatory cells, which in turn produce 
pro-fibrotic mediators such as transforming growth factor β (TGFβ), platelet derived growth 
factor (PDGF) and interleukin-4 (IL-4) (3). Depending on the organ involved, these cytokines 
activate fibroblasts, hepatic stellate cells, mesangial cells or tubular epithelial cells, leading to 
an increased production of extracellular matrix proteins. In later stages of the fibrotic diseases, 
pro-fibrotic cytokines are often produced by resident cells. In addition to an increased 
production of extracellular matrix proteins, an imbalance between matrix degrading enzymes 
and their inhibitors might contribute the development of fibrosis. The matrix components 
accumulate in the extracellular compartment and disrupt the physiological tissue structure, 
often causing a severe functional impairment of the involved organs.  
Tumor necrosis factor α (TNFα) is produced by a wide variety of hematopoietic and non-
hematopoietic cells such as macrophages, CD4+ and CD8+ T cells, B cells, NK cells, 
neutrophils, smooth muscle cells, endothelial cells and fibroblasts (4). TNFα exists in two 
forms, a membrane bound and a soluble form, both of which are functional and contribute to 
the effects of TNFα (5, 6). Human TNFα is expressed as a precursor protein with a molecular 
mass of 26 kDa, which is then enzymatically cleaved to give a 17 kDa active form. Under 
physiological conditions, TNFα forms homotrimers which interact and cross-link with the 
respective receptors. TNFα binds with high affinity to two transmembrane receptors, TNF 
receptor 1 (TNFR1, also referred to as TNFRβ, p55 or CD120a) and TNF receptor 2 (TNFR2, 
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TBFRα, p75) (7). The homology between the two receptors is limited, especially within their 
intracellular regions (7, 8). The expression of TNFR1 and TNFR2 is differentially regulated. 
The expression of TNFR1 seems to be controlled by a house-keeping promoter with high 
basal activity and only weak response to stimulation. In contrast, the expression of TNFR2 is 
strongly influenced by external factors (9, 10). TNFR1 can mediate almost all activities of 
TNFα, whereas TNFR2 transduces signals at physiological levels only in a few cell types 
such as T cells (11). However, TNFR2 plays an important role in fine tuning TNFR1 
signaling. Due to its higher affinity, TNFR2 binds TNFα preferentially at low concentrations. 
TNFα is then passed to neighboring TNFR1 molecules, which allows TNFα to exert its effects 
at lower concentrations (12).  
The efficacy of TNFα antagonists in inflammatory diseases such as rheumatoid arthritis, 
spondylarthropathies and Crohn’s disease has been demonstrated in numerous clinical trials 
and plays an important  role in the treatment of patients with these diseases (13-15). Recent 
reports suggest that TNFα antagonists might also be beneficial for the treatment of fibrotic 
disorders. In a retrospective case-series, treatment with etanercept appeared to be efficacious 
in improving active inflammatory joint disease in SSc patients. Etanercept was generally well 
tolerated and skin fibrosis was reduced under treatment in this uncontrolled study (16). 
Similarly, another case-series reported on the outcome of four patients with systemic sclerosis 
(SSc) and erosive arthritis treated with TNFα antagonists (17). TNFα antagonists not only 
improved arthritis, but the modified Rodnan skin score as a clinical score for the 
quantification of skin fibrosis in SSc patients decreased also in all patients with reductions of 
greater than 50 % in three patients. Another case report showed stabilization of lung fibrosis 
in a patient with SSc under treatment with infliximab (18). Three additional open-label studies 
with etanercept or infliximab have been published in abstract form (19-21). Treatment was 
overall well tolerated in these case-series including long-term application for a mean of 24 
months on one study. The modified Rodnan skin score was stable or improved, and amino-
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terminal propeptide of type III procollagen as a biomarker for fibrosis decreased under 
treatment in one study. While definite conclusions cannot be drawn from open-label, 
uncontrolled case-series, these data suggest that TNFα antagonists might play a role in the 
treatment of fibrotic diseases. On the other hand, TNFα was long considered an anti-fibrotic 
cytokine and treatment with TNFα antagonists might not be safe in SSc patients. Accordingly, 
another case report showed that treatment with adalimumab was associated with fatal 
exacerbation of fibrosing alveolitis in a patient with SSc (22). Similarly, TNFα antagonists 
have been associated with fibrosing alveolitis in patients with rheumatoid arthritis in a number 
of case-reports (23). Thus, before TNFα antagonists can be considered for the treatment of 
patients with fibrotic diseases the following open questions have to be addressed: What is the 
experimental evidence for TNFα antagonists for the treatment of fibrotic disorders? Do 
molecular studies demonstrate a pro-fibrotic role of TNFα or do they rather show anti-fibrotic 
effects of TNFα? This review will discuss in detail the results of in-vitro and in-vivo studies 
analyzing the role of TNFα signaling in organ fibrosis with focus on skin and pulmonary 
fibrosis to provide a basis for further clinical studies in rheumatic diseases.  
 4
Effects of TNFα on extracellular matrix remodeling in-vitro 
 
Evidence for anti-fibrotic effects of TNFα 
The effects of TNFα on the production of collagen and the turnover of extracellular matrix 
have been analyzed in numerous studies. Mauviel and coworkers demonstrated that TNFα 
inhibits the synthesis of type I collagen in cultured dermal fibroblasts on the transcriptional 
level, resulting in a dose-dependent reduction of the production of type I collagen as measured 
by radioimmunoassay and gel electrophoresis (24, 25). In addition, TNFα inhibited the 
synthesis of type III collagen and fibronectin (24). TNFα plays also an important role for the 
inhibitory effects of CD4 T cells on the collagen production in dermal fibroblasts. Th1 and 
Th2 cells activated by CD3 crosslinking as well as preparations of Th1 and Th2 plasma 
membranes significantly decreased the production of collagen in dermal fibroblasts from 
healthy controls (26). TNFα antagonism by addition of soluble TNFR1, but not neutralization 
of IL-4 and IFNγ significantly reduced the inhibitory activity of T cells on matrix production. 
Addition of Th2 membranes to fibroblasts stimulated with the pro-fibrotic cytokines TGFβ 
and IL-4 abrogated the increased production of collagen, demonstrating that the inhibition by 
Th2 membranes were dominant over the stimulatory effects of TGFβ and IL-4. Interestingly, 
these anti-fibrotic mechanisms of TNFα via T cell membranes might not be fully active in 
fibrotic diseases, because SSc fibroblasts were resistant to inhibition by Th2 membranes and 
less sensitive to inhibition by Th1 membranes compared to healthy fibroblasts.  
The inhibitory effects of TNFα on the production of collagen are partially mediated by NF-
κB. Using electromobility shift assays and supershift assays, Kouba and coworkers 
demonstrated that RelA/ NF-κB (p65ּp50) complexes bind to a cis-element adjacent in the 
promotor of col1A2 (27). Mutation of the NF-κB binding site almost completely prevented 
the inhibitory effects of TNFα. The crucial role of NF-κB for the downregulation of col1A2 
synthesis was confirmed using fibroblasts deficient for the NF-κB essential modulator 
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(NEMO) (28). NEMO is activated in response to inflammatory stimuli and activates the 
associated I-κB kinases (IKKs). In turn, IKKs phosphorylate I-κB, the inhibitor of NF-κB. 
Phosphorylated I-κB dissociates from NF-κB, which can then enter the nucleus and activate 
transcription of NF-κB dependent genes. NEMO deficiency prevented the inhibitory effects of 
TNFα on the col1A2 transcription. Similar results were also obtained in dermal fibroblasts 
transfected with dominant negative forms of the Inhibitor of NF-κB (I-κB) kinase α (IKKα) 
(28). 
In addition to direct effects on the transcription of collagens, TNFα might exert anti-fibrotic 
properties by interfering with TGFβ signaling cascades (29). Incubation of neonatal human 
foreskin fibroblasts with TNFα one hour prior to stimulation with TGFβ prevented Smad 
specific gene transcription as analyzed with reporter constructs of the Smad 3/4 binding 
element (SBE). The inhibitory effect of TNFα on the activation of TGFβ-dependent Smad 
signaling was not mediated by an induction of the inhibitory Smad7, but rather by AP-1 
dependent pathways. JunB and c-jun, two members of the AP-1 family, are strongly induced 
in dermal fibroblasts upon stimulation with TNFα. Overexpression of JunB and c-jun 
abrogated the Smad3 dependent transactivation of the SBE reporter construct in a dose-
dependent manner. The import role of AP-1 signaling for the inhibitory effect of TNFα was 
further supported by experiments demonstrating that expression of antisense c-Jun mRNA 
prevented the inhibition of TGFβ/Smad signaling by TNFα. The inhibitory effects of JunB 
and c-jun on Smad signaling are mediated by two distinct mechanisms. Co-precipitation 
assays and electromobility shift assays demonstrated that JunB and c-jun form 
heterocomplexes with Smad3 and that JunB and c-jun reduce the binding of Smad3 to its 
cognate cis-DNA-element. These findings suggest that Smad3-AP-1 interactions may 
sequester Smad3 and compete against Smad3 binding to DNA. Furthermore, JunB and c-jun 
bind p300, a cofactor essential for optimal transcription of Smad-regulated genes. Because the 
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amount of p300 in the nucleus is limited, competition of JunB and c-jun with Smad3 for p300 
can efficiently prevent Smad-signaling (29).  
Besides its direct effects on the synthesis of extracellular matrix proteins, TNFα regulates also 
the expression of matrix degrading enzymes and their inhibitors. TNFα induced dose-
dependently MMP-1 mRNA and protein in dermal, gingival and synovial fibroblasts (30, 31). 
Furthermore, higher concentrations of TNFα reduced the expression of TIMP-1, thereby 
promoting the degradation of extracellular matrix proteins (32). The effects of TNFα on the 
collagen synthesis and the production of MMPs and TIMPs are not restricted to fibroblasts, 
and are  also found in other cell types (33).  
 
Evidence for pro-fibrotic effects of TNFα 
In contrast to the results discussed above, a recent study suggested that TNFα might promote 
a pro-fibrotic phenotype in murine intestinal myofibroblasts in-vitro (34). In vimentin and α-
smooth muscle actin positive myofibroblasts isolated from wildtype-mice, murine TNFα 
stimulated collagen synthesis, increased expression of TIMP-1 and decreased activity of 
MMP-2. Similar results were also obtained with myofibroblasts from mice homozygous for 
the disruption of the gene for TNFR1 (TNFR1-/-). However, no induction of collagen was 
observed in myofibroblasts from TNFR2-/- mice and from TNFR1-/- and TNFR2-/- double-
knockout mice, suggesting that the pro-fibrotic effect of TNFα on myofibroblasts is mediated 
by signaling via TNFR2. It remains unclear, why the effects of TNFα on the production of the 
extracellular matrix in this study differed from the results of previous studies. The 
concentrations of TNFα used were within the range of other studies and species specific 
differences can be excluded, because murine fibroblasts respond to TNFα with an 
upregulation of collagen and induction of MMPs similar to human fibroblasts (28).  However, 
the effects of TNFα might be cell-type and organ specific and intestinal myofibroblasts might 
react differently from other cell types.  
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Another in-vitro study proposed also a pro-fibrotic effect of TNFα, indirectly via an induction 
of TGFβ (35). Incubation of Swiss 3T3 cells, a mouse fibroblast cell line, and primary mouse 
fibroblasts with TNFα stimulated the expression of TGFβ mRNA and protein. The induction 
of TGFβ by TNFα was blocked by inhibitors of the ERK-specific mitogen activated protein 
kinase pathway. However, it remains unclear, whether the induction of TGFβ is sufficient to 
overcome the inhibitory effects of TNFα on the collagen production, since the authors did not 
analyze the expression of collagen. The induction of TGFβ upon stimulation with TNFα 
might therefore represent a counter-regulatory mechanism to compensate for the inhibitory 
effects of TNFα on Smad signaling. 
Phagocytosis of collagen has been suggested to play a role in the homeostasis of the 
extracellular matrix and inhibition of the phagocytosis might therefore lead to fibrosis (36). 
Although this mechanism is currently not considered to play a major role, it might further 
enhance fibrotic processes. TNFα has been suggested to inhibit the phagocytosis of collagen 
by fibroblasts and might therefore enhance fibrotic processes also via this mechanism. 
Incubation with TNFα increased slightly the expression of α1β1- and α2β1-integrin, which 
bind collagen in human gingival fibroblasts, but the binding of collagen was significantly 
decreased, suggesting an inactivation of the binding sites for collagen by TNFα (37). 
Consistent with decreased binding, the percentage of phagocytosed collagen beads per cell 
and the proportion of phagocytically active gingival fibroblasts were reduced in a dose-
dependent manner by TNFα.  
 
The role of TNFα in different in-vivo models of tissue fibrosis  
 
Effects of overexpression of TNFα on the turnover of extracellular matrix 
Results from animal studies overexpressing TNFα are inconsistent regarding the effects on 
extracellular matrix synthesis. A number of studies indicate pro-fibrotic effects of TNFα.   
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For instance, overexpression of TNFα in the lungs has been linked to fibrosis. Using a 
replication deficient adenovirus, a prolonged overexpression of TNFα for 7-10 days was 
achieved in the lungs of rats (38). This local overexpression resulted in a severe infiltration of 
the lungs by neutrophils, macrophages and lymphocytes. Later on, increased expression of 
TGFβ was detected and myofibroblasts appeared. After the inflammation subsided, a patchy 
fibrosis developed, which persisted beyond day 64. These data are supported by the analysis 
of peripheral CD4 T cells from patients with idiopathic pulmonary fibrosis. In comparison to 
normal subjects, these CD4 T cells synthesized higher levels of TNFα as analyzed by 
intracellular FACS staining (39). The role of TNFα in pulmonary fibrosis has also been 
analyzed with transgenic mice overexpressing murine TNFα in the lungs under the control of 
the human surfactant protein C promoter. These mice developed spontaneously a chronic 
lymphocytic alveolitis, and its severity correlated with the expression of TNFα mRNA in the 
lungs (40). The transgenic mice had also higher lung volumes, pulmonary hypertension and 
decreased elastic recoil compared to control mice. Histologically, the authors observed 
thickened alveolar walls due to accumulation of desmin-containing fibroblasts and collagen 
fibers, a phenotype resembling idiopathic pulmonary fibrosis.  
Similar profibrotic effects of TNFα were observed in animal models of congestive heart 
failure using modified TNFα transgenic mice (41, 42). Accordingly, continuous subcutaneous 
infusion of TNFα led to abundant infiltration with polymorphonuclear leukocytes and 
stimulated the growth of dermal fibroblasts resulting in an increased local deposition of 
collagen (43). 
While these studies suggest that TNFα is a pro-fibrotic cytokine, other studies in mice 
overexpressing TNFα indicate anti-fibrotic effects and a protective role of TNFα in models of 
experimental fibrosis. A more recent study by a different group on the same transgenic mice 
with lung specific TNFα expression under the control of the human surfactant protein C 
promoter led to different conclusions. Fujita and colleagues confirmed the presence of chronic 
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pulmonary inflammation and increased lung volumes with an increase of the total amount of 
hydroxyproline in the lungs (44). However, when the hydroxyproline content was normalized 
for the lung weight, no differences were observed between TNFα transgenic mice and 
controls. Accordingly, Fujita et al. observed only very little fibrosis in the lungs of transgenic 
animals. Furthermore, TNFα transgenic mice were resistant to experimental pulmonary 
fibrosis induced by bleomycin or overexpression of TGFβ. In contrast to wildtype mice, no 
increase of the hydroxyproline content and no fibrotic changes in histological sections were 
observed in TNFα transgenic mice. It needs to be stressed that the determination of the 
hydroxyproline content is often misleading, especially under inflammatory conditions, where 
inflammatory cells produce C1q which contains also hydroxyproline and due to the fact that 
collagen type III contains 30 percent more hydroxyproline than type I collagen. The anti-
fibrotic role of TNFα in experimental pulmonary fibrosis in these animals was further 
supported by experiments demonstrating that application of recombinant human TNFα 
attenuated bleomycin-induced pulmonary fibrosis in wildtype mice.  
An anti-fibrotic effect of TNFα was also reported by Buck and coworkers (45). They 
demonstrated that inoculation of nude mice with Chinese hamster ovary cells secreting TNFα 
resulted in a decreased collagen synthesis in the skin, which also led to impaired wound 
healing and was paralleled by decreased expression of TGFβ. Similar results were obtained 
by the same group for the liver (46).  
 
Studies with inhibitors of TNFα  
Studies by Piguet and coworkers demonstrated that TNFα antagonists can reduce significantly 
the accumulation of extracellular matrix in mouse models of silica- and bleomycin induced 
pulmonary fibrosis (47, 48). Silica and bleomycin stimulate the expression of TNFα and lead 
to a patchy fibrosis after 15 days. Infusion of anti-TNFα-antibodies or recombinant soluble 
TNFR1 prevented the development of fibrosis in both models. Treatment of established 
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fibrosis with soluble TNFR1 was also effective as demonstrated by experiments with soluble 
TNFR1 administered 25 days after bleomycin and silica. Accordingly, continuous infusion of 
recombinant TNFα augmented the fibrotic process strongly (47).  
Beneficial effects of TNFα inhibitors were also found in a transplantation model (49). When 
tracheas from Brown-Norway rats were transplanted into Lewis rats, obliterative airway 
disease with inflammatory infiltrates and fibroproliferative lesions developed. Luminal 
occlusion occurred in 58 % of untreated animals after 14 days. When animals were treated 
with antibodies against TNFα or RDP-58, a translational inhibitor of TNFα, fibroproliferative 
lesions were strongly reduced and the percentage of luminal occlusion decreased from 58 % 
to 32 %. Similar antifibrotic effects with anti-TNFα-antibodies were observed in experimental 
crescentic glomerulonephritis as a model for kidney fibrosis (50).  
 
Lessons from mice deficient for TNF receptors 
Numerous studies have analyzed the outcome of mice deficient for either TNFR1 (TNFR1-/-), 
TNFR2 (TNFR2-/-) or both receptors (TNFR1/2-/-) in different models of organ fibrosis. In 
contrast to experiments with TNFα transgenic mice, these studies demonstrate uniformly that 
inhibition of signaling via TNFR1 and TNFR2 prevents the development of fibrosis. For 
instance, TNFR1/2-/- mice were protected from experimental pulmonary fibrosis induced by 
silica, asbestos and bleomycin (51-53). In contrast to wildtype mice, TNFR1/2-/- mice did not 
demonstrate significant inflammation or increased proliferation in the lungs after exposure to 
pro-fibrotic agents, the induction of TNFα was diminished and there was no increased 
deposition of extracellular matrix. Similar results were obtained with TNFR1-/- and TNFR1/2 -
/- mice in different models of liver and kidney fibrosis, while TNFR2-/- were not protected 
from kidney and liver fibrosis (54-58).  
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Summary and conclusion 
In-vitro and in-vivo experiments about the role of TNFα in fibrosis are in part contradictory 
and do not allow definite conclusions on the role of TNFα as a pro-fibrotic mediator or an 
anti-fibrotic cytokine. The majority of in vitro studies show anti-fibrotic effects of TNFα in 
that it suppresses the production of collagen, reduces the expression of TIMPs and stimulates 
the release of MMPs, thereby preventing the accumulation of extracellular matrix. The 
intracellular signaling pathways mediating these effects have been identified and include 
activation of JunB and c-Jun. However, under certain circumstances, TNFα might have pro-
fibrotic effects in vitro. In particular myofibroblasts, which are thought to play a central role 
in fibrotic disorders such as SSc by releasing large amounts of extracellular matrix proteins, 
might react differentially to TNFα than resting fibroblasts.  
While the in vitro studies overall favor TNFα as an anti-fibrotic cytokine, different in-vivo 
animal studies with antagonists of TNFα and mice lacking TNFR1 or both TNFα receptors 
demonstrated that inhibition of TNFα signaling can prevent fibrosis. On the other hand, 
studies on TNFα transgenic mice yielded different results, with most studies suggesting a pro-
fibrotic role of TNFα.  
In our opinion, these differences in the results between in-vitro and in-vivo studies might be 
explained by the inflammatory component in animal models of experimental fibrosis (Figure). 
Most of these models depend critically on a strong inflammatory component at the initial 
stages as a trigger for the later development of fibrosis. TNFα as a major pro-inflammatory 
stimulus has been shown to play an important role for the activation of inflammatory cells. In-
vitro, inflammatory conditions and cellular inflammatory infiltrates are lacking and TNFα can 
exert its direct effects on the matrix-producing cells. In our view, a likely scenario is that the 
direct anti-fibrotic effects of TNFα on fibroblasts might be outweighed in experimental 
models of fibrosis by its important role in driving inflammation.  
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Thus, to predict the effects of anti-TNFα treatments in human fibrotic diseases, the key 
question is whether inflammation triggers and perpetuates the development of fibrosis in 
humans. The role of inflammation in human fibrotic diseases is less clear than initially 
thought, and might differ between the specific organs and also depend on other parameters 
such as disease duration. For example, in SSc skin fibrosis, inflammatory infiltrates are 
thought to play an important role in very early disease stages, but are rarely seen in later 
stages of the disease. This might predict that anti-TNFα treatments could be a promising anti-
fibrotic strategy for very early inflammatory skin fibrosis in SSc, while it might be even 
deleterious for later non-inflammatory stages of skin fibrosis.  
Accordingly, effects on lung fibrosis might be different from skin fibrosis. Inflammation is 
thought to play a more important role in interstitial pulmonary fibrosis associated with SSc 
with recurrent alveolitis triggering progression of fibrosis during the course of the disease. If 
this concept holds true, patients with pulmonary fibrosis and alveolitis might benefit from 
anti-TNFα treatments while the effects on lung fibrosis might be again deleterious in patients 
having no evidence for inflammation/alveolitis. However, it has to be emphasized that this 
concept is theoretical, because so far no controlled study has looked at effects of TNFα in 
inflammatory phases of SSc. 
Taken together, available molecular and cellular studies do not allow definite conclusions on 
the role of TNFα in fibrotic diseases. More experimental studies are necessary with a 
particular focus on fibrotic animal models that are independent of inflammation as a trigger 
for the fibrotic process. Cellular studies have been lacking a complete description of the 
transcriptom after TNF or anti-TNF treatment, which would provide a more comprehensive 
analysis and could together with a proteomics study elucidate the contradictory findings 
reported so far, instead by analyzing only selective and expected pathways.  
Open-label uncontrolled studies with TNFα inhibitors in SSc appear to be promising. 
However, from the existing literature, there are concerns that treatment with TNFα 
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antagonists could lead to progression of fibrosis. Therefore, TNFα antagonists should not be 
used in daily clinical practice for the treatment of patients with fibrotic diseases until these 
concerns are cleared. To elucidate the definitive clinical effects of TNFα antagonists in 
fibrotic diseases, placebo-controlled trials need to be performed. Patients with inflammatory 
stages of the fibrotic disease are most likely to respond, while patients in non-inflammatory 
stages of fibrosis might even show deleterious effects. Regarding safety issues, these trials 
need to focus on fibrosis outcomes in addition to the conventional safety issues such as 
infection and malignancy, and they need to be designed with sufficient statistical power to 
exclude potentially harmful effects.  
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Figure legends 
 
Figure 1:  
TNFα exerts prominent pro-inflammatory properties and activates inflammatory cells in the 
initial phases of experimental models of fibrosis. Inflammatory cells secret pro-fibrotic 
mediators, which activate fibroblasts. Activated fibroblasts produce increased amounts of 
extracellular matrix, resulting in tissue fibrosis in later stages. On the other hand, TNFα 
inhibits the directly the synthesis of extracellular matrix proteins in fibroblasts in vitro in most 
studies. The net effects of these contrary effects in human fibrotic diseases, where 
inflammation is often less pronounced than experimental models, remains unclear.  
Tables 
 
 
In vitro studies suggesting anti-fibrotic effects In vitro studies suggesting pro-fibrotic effects 
Mechanism of action Cell type Reference 
 
Mechanism of action Cell type Reference 
 
Inhibition of the transcription of 
fibronectin, type I and type III 
collagen  
dermal fibroblasts (24, 25) 
 
Induction of MMP-1  dermal, gingival 
and synovial 
fibroblasts 
(30, 31) 
Reduction of the expression of 
TIMP-1 
uterine fibroblasts (32) 
Stimulation of the collagen 
synthesis, the expression of TIMP-1 
and MMP-2 via TNFR2 
intestinal 
myofibroblasts 
(34) 
Inhibition of TGFβ mediated 
activation of Smad3 
neonatal foreskin 
fibroblasts 
(29) 
 
Induction of TGFβ via Erk 
dependent pathways 
Swiss 3T3 cells and 
primary mouse 
(35) 
 
fibroblasts 
Mediator of the inhibitory effects of 
CD4 T cells on the collagen 
production  
dermal fibroblasts (26) Inhibition of the phagocytosis of 
collagen  
fibroblasts  (37)
Table 1: Overview of in vitro studies on the pro- and anti-fibrotic effects of TNFα.  
 
 
 
In vivo studies suggesting anti-fibrotic effects In vivo studies suggesting pro-fibrotic effects 
Model   Organ Reference
 
Model Organ  Reference 
 
Reduction of the accumulation of extracellular 
matrix in mouse models of silica- and bleomycin 
induced pulmonary fibrosis by TNFα antagonists  
lungs    (47, 48)
 
Induction of pulmonary fibrosis in mice 
overexpressing TNFα 
lungs (38, 40)
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Protection from experimental pulmonary fibrosis 
induced by silica, asbestos and bleomycin in 
TNFR1/2-/- mice 
lungs    (51-53)
 
Induction of interstitial myocardial fibrosis by 
overexpression of TNFα  
heart (41)
Reduced fibroproliferative lesions after allogeneic 
transplantation of rat tracheas by treatment TNFα 
antagonists 
trachea    (49) Increased deposition of collagen after 
subcutaneous infusion of TNFα  
skin (43)
 
Decreased collagen synthesis in the skin of nude 
mice injected with CHO cells overexpressing TNFα 
skin   (46)
Table 2: Overview of studies on the role of TNFα in animal models of skin and pulmonary fibrosis.  
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